Recursion Pharmaceuticals, Inc.

RXRX Healthcare Biotechnology

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.47 0.69 −16.59%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−3.8×
Dividend yield
—
F-score
3/9
Altman Z
0.37
Beneish M
−1.72
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '19 Jan '20 Dec '20 Jan '21 Dec '21 Jan '22 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
76.40 — 266.44 — 534.72 — 569.81 438.14 714.27 812.85
Total non-current assets
25.03 — 32.15 — 75.63 — 131.47 215.56 734.33 661.29
Total Assets
101.43 — 298.59 — 610.35 — 701.29 653.70 1,448.60 1,474.13
Total current liabilities
6.68 — 23.10 — 46.66 — 100.27 93.17 187.47 147.71
Total non-current liabilities
17.90 — 33.46 — 20.75 — 115.22 97.09 226.34 195.56
Total liabilities
24.59 — 56.56 — 67.41 — 215.48 190.26 413.82 343.27
Common Equity (Total)
(124.26) — (206.29) — 542.94 — 485.81 463.44 1,034.78 1,130.87
Shareholders Equity (Total)
76.84 — 242.02 — 542.94 — 485.81 463.44 1,034.78 1,130.87
Total Debt
12.42 14.12 11.41 9.97 0.63 44.96 0.54 1.10 19.02 9.56

Show all line items

In millions of $ except per-share values · columns are period end dates